Denosumab for the reduction of bone loss in postmenopausal osteoporosis: A review

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1547-1559

  Bridgeman, Mary Barna ^a,b   Pathak, Rolee ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b Capital Health Regional Medical Center   (United States)

^c ST JOSEPH S REGIONAL MEDICAL CENTER   (United States)

Author keywords

Denosumab; Monoclonal antibody; Osteoporosis; RANKL

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; ANTIESTROGEN; ANTIINFECTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CARBONATE PLUS RISEDRONIC ACID; CORTICOSTEROID; DENOSUMAB; IBANDRONIC ACID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ACRODERMATITIS; APPENDICITIS; ARTHRALGIA; BACKACHE; BIBLIOGRAPHIC DATABASE; BONE DENSITY; BONE NECROSIS; BRONCHITIS; CARDIOVASCULAR DISEASE; CELLULITIS; CONSTIPATION; CYSTITIS; DERMATITIS; DIVERTICULITIS; DRUG BINDING; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHAGIA; ECZEMA; ESOPHAGITIS; EYE INFLAMMATION; FEMALE; FLATULENCE; FRACTURE NONUNION; HIP; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOCALCEMIA; INFECTION; INFLUENZA; JAW OSTEONECROSIS; KIDNEY DISEASE; LEG CRAMP; LIMB PAIN; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; MUSCULOSKELETAL PAIN; MYALGIA; NEOPLASM; OSTEOARTHRITIS; OSTEOLYSIS; OSTEOPOROSIS; PANCREATITIS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PYELONEPHRITIS; RADIUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHINITIS; RHINOPHARYNGITIS; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS;

EID: 82855179448     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.10.008     Document Type: Review

References (34)

1. The management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010, 17:25-54. North American Menopause Society.
2. Looker A.C., Melton L.J., Harris T.B., et al. Prevalence and trends in low femur bone density among older US adults: NHANES 2005-2006 compared with NHANES III. J Bone Miner Res 2010, 20:64-71.
3. Fast Facts National Osteoporosis Foundation, Accessed January 9, 2011. http://www.nof.org/node/40.
4. Melton L.J., Thamer M., Ray N.F., et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997, 12:16-23.
5. Melton L.J., Atkinson E.J., O'Connor M.K., et al. Bone density and fracture risk in men. J Bone Miner Res 1998, 13:1915.
6. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 1994, 4:368-381. World Health Organization Study Group.
7. New Clinician's Guide to Prevention and Treatment of Osteoporosis National Osteoporosis Foundation, Accessed January 7, 2011. http://www.nof.org/professionals/Clinicians_Guide.htm.
8. Vondraneck S.F. Managing osteoporosis in postmenopausal women. Am J Health Syst Pharm 2010, 67(Suppl 3):S9-S19.
9. Fosamax (alendronate sodium) [prescribing information] 2010, Merck & Co Inc, Whitehouse Station, NJ.
10. Boniva (ibandronate sodium) [prescribing information] 2010, Genentech USA Inc, San Francisco, Calif.
11. Actonel (risedronate sodium) [prescribing information] 2010, Warner Chilcott Pharmaceuticals Inc, Mason, Oh.
12. Reclast (zoledronic acid) [prescribing information] 2010, Novartis Pharmaceuticals Corp, East Hanover, NJ.
13. Evista (raloxifene hydrochloride) [prescribing information] Accessed October 18, 2011. http://pi.lilly.com/us/evista-pi.pdf.
14. Miacalcin (calcitonin salmon) [prescribing information] 2006, Novartis Pharmaceuticals Corp, East Hanover, NJ.
15. Fortical (calcitonin-salmon [rDNA origin]) [prescribing information] 2010, Upsher-Smith Laboratories, Minneapolis, Minn.
16. Forteo (teriparatide [rDNA origin] injection) [prescribing information] 2010, Eli Lilly and Co, Indianapolis, Ind.
17. Prolia (denosumab) [prescribing information] 2010, Amgen Inc, Thousand Oaks, Calif.
18. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21:115-137.
19. Miller P.D. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep 2009, 7:18-22.
20. Lacey D.L., Timms E., Tan H.-L., et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
21. Eghbali-Fatourechi G., Khosla S., Sanyal A., et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111:1221-1230.
22. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular disease. JAMA 2004, 292:490-495.
23. Body J.J., Facon T., Coleman R.E., et al. A study of the biological receptor activator of nuclear factor K-B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastasis from breast cancer. Clin Cancer Res 2006, 12:1221-1228.
24. Bekker P.J., Holloway D.L., Rasmussen A.S., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059-1066.
25. McClung M.R., Lewiecki M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.
26. Lewiecki E.M., Miller P.D., McClung M.R., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007, 22:1832-1841.
27. Miller O.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in post menopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008, 43:222-229.
28. Bone H.G., Bolognese M.A., Yuen C.K., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008, 93:2149-2157.
29. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361:756-765.
30. Brown J.P., Prince R.L., Deal C., et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 24:153-161.
31. Kendler D.L., Roux C., Benhanou C.L., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010, 25:72-81.
32. Cada D.J., Levien T.L., Baker D.R. Denosumab. Hosp Pharm 2010, 45:785-793.
33. Aghaloo T.l., Felsenfeld A.L., Tetradis S. Osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 2010, 68:959-963.
34. Approved Risk Evaluation Mitigation Strategies, Prolia (Denosumab) Injection US Food and Drug Administration, Accessed January 9, 2011. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM214383.pdf.